Thr514
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Thr514  -  CRMP-2 (mouse)

Site Information
sVtPktVtPAssAkt   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 454386

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 3 , 7 , 9 , 10 , 11 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 23 , 24 , 25 , 26 , 27 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 48 , 49 , 50 , 52 ) , mutation of modification site ( 6 , 28 , 51 ) , phospho-antibody ( 1 , 5 , 6 , 12 , 22 , 47 , 51 ) , western blotting ( 1 , 5 , 6 , 12 , 22 , 47 , 51 )
Disease tissue studied:
bipolar disprder ( 1 ) , brain cancer ( 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 ) , neuroblastoma ( 25 , 51 ) , neuroendocrine cancer ( 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 )
Relevant cell line - cell type - tissue:
'3T3-L1, differentiated' (adipocyte) ( 7 ) , 'brain, cerebral cortex' ( 29 , 47 ) , 'brain, embryonic' ( 23 , 30 , 32 , 35 , 36 , 39 , 40 , 42 , 43 , 46 , 48 ) , 'brain, forebrain' ( 45 ) , 'brain, hippocampus' ( 1 , 47 , 51 ) , 'fat, brown' ( 26 ) , 'neuron, cortical' ( 28 ) , 'stem, induced pluripotent' ( 1 ) , brain ( 10 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 26 , 27 , 31 , 33 , 34 , 37 , 38 , 41 , 44 , 49 , 50 , 52 ) , COS (fibroblast) ( 6 ) , heart ( 26 ) , liver ( 26 ) , lung ( 26 ) , MEF (fibroblast) ( 9 ) , MEF (fibroblast) [TSC2 (mouse), homozygous knockout] ( 24 ) , N1E-115 (neuron) ( 25 , 51 ) , neuron-'brain, cerebral cortex' ( 5 , 51 ) , neuron-'brain, hippocampus' ( 22 ) , neuron-dorsal root ganglia ( 6 , 12 ) , pancreas ( 26 ) , PC-12 (chromaffin) [TrkA (rat), transfection] ( 11 ) , RAW 264.7 (macrophage) ( 3 ) , SH-SY5Y (neural crest) ( 51 ) , spleen ( 26 ) , testis ( 26 )

Upstream Regulation
Regulatory protein:
APP (human) ( 47 ) , APP (mouse) ( 47 ) , axin 1 (mouse) ( 22 ) , CDK5 (human) ( 47 ) , CDK5 (mouse) ( 51 ) , PSEN1 (mouse) ( 47 )
Putative in vivo kinases:
GSK3A (human) ( 5 ) , GSK3B (mouse) ( 51 )
Treatments:
bisindolylmaleimide ( 6 ) , CT-99021 ( 51 ) , insulin ( 7 ) , kainic_acid ( 6 ) , lithium ( 1 ) , LPA ( 25 ) , LY294002 ( 7 ) , metamfetamine ( 1 ) , MG132 ( 12 ) , MK-2206 ( 7 ) , nerve_damage ( 12 ) , Sem3A ( 51 ) , TDZD-8 ( 12 )

Downstream Regulation
Effects of modification on biological processes:
cell growth, altered ( 28 ) , cell motility, induced ( 5 ) , cytoskeletal reorganization ( 5 )

References 

1

Tobe BTD, et al. (2017) Probing the lithium-response pathway in hiPSCs implicates the phosphoregulatory set-point for a cytoskeletal modulator in bipolar pathogenesis. Proc Natl Acad Sci U S A 114, E4462-E4471
28500272   Curated Info

2

Sacco F, et al. (2016) Glucose-regulated and drug-perturbed phosphoproteome reveals molecular mechanisms controlling insulin secretion. Nat Commun 7, 13250
27841257   Curated Info

3

Pinto SM, et al. (2015) Quantitative phosphoproteomic analysis of IL-33-mediated signaling. Proteomics 15, 532-44
25367039   Curated Info

4

Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704
24719451   Curated Info

5

Morgan-Smith M, et al. (2014) GSK-3 signaling in developing cortical neurons is essential for radial migration and dendritic orientation. Elife 3, e02663
25073924   Curated Info

6

Marques JM, et al. (2013) CRMP2 Tethers Kainate Receptor Activity to Cytoskeleton Dynamics during Neuronal Maturation. J Neurosci 33, 18298-310
24227739   Curated Info

7

Humphrey SJ, et al. (2013) Dynamic Adipocyte Phosphoproteome Reveals that Akt Directly Regulates mTORC2. Cell Metab 17, 1009-20
23684622   Curated Info

8

Qin Z, et al. (2013) Isoaspartate accumulation in mouse brain is associated with altered patterns of protein phosphorylation and acetylation, some of which are highly sex-dependent. PLoS One 8, e80758
24224061   Curated Info

9

Wu X, et al. (2012) Investigation of receptor interacting protein (RIP3)-dependent protein phosphorylation by quantitative phosphoproteomics. Mol Cell Proteomics 11, 1640-51
22942356   Curated Info

10

Goswami T, et al. (2012) Comparative phosphoproteomic analysis of neonatal and adult murine brain. Proteomics 12, 2185-9
22807455   Curated Info

11

Biarc J, Chalkley RJ, Burlingame AL, Bradshaw RA (2012) The induction of serine/threonine protein phosphorylations by a PDGFR/TrkA chimera in stably transfected PC12 cells. Mol Cell Proteomics 11, 15-30
22027198   Curated Info

12

Wakatsuki S, Saitoh F, Araki T (2011) ZNRF1 promotes Wallerian degeneration by degrading AKT to induce GSK3B-dependent CRMP2 phosphorylation. Nat Cell Biol 13, 1415-23
22057101   Curated Info

13

Guo A (2011) CST Curation Set: 12728; Year: 2011; Biosample/Treatment: tissue, brain/untreated; Disease: brain cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

14

Guo A (2011) CST Curation Set: 12729; Year: 2011; Biosample/Treatment: tissue, brain/untreated; Disease: brain cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

15

Guo A (2011) CST Curation Set: 12730; Year: 2011; Biosample/Treatment: tissue, brain/untreated; Disease: brain cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

16

Guo A (2011) CST Curation Set: 12732; Year: 2011; Biosample/Treatment: tissue, brain/untreated; Disease: brain cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) CDKs Substrate Antibody Cat#: 2324, PTMScan(R) Phospho-CDK Substrate Motif (K/RS*PXK/R) Immunoaffinity Beads Cat#: 1981
Curated Info

17

Guo A (2011) CST Curation Set: 12733; Year: 2011; Biosample/Treatment: tissue, brain/untreated; Disease: brain cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) CDKs Substrate Antibody Cat#: 2324, PTMScan(R) Phospho-CDK Substrate Motif (K/RS*PXK/R) Immunoaffinity Beads Cat#: 1981
Curated Info

18

Guo A (2011) CST Curation Set: 12734; Year: 2011; Biosample/Treatment: tissue, brain/untreated; Disease: brain cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) CDKs Substrate Antibody Cat#: 2324, PTMScan(R) Phospho-CDK Substrate Motif (K/RS*PXK/R) Immunoaffinity Beads Cat#: 1981
Curated Info

19

Guo A (2011) CST Curation Set: 12735; Year: 2011; Biosample/Treatment: tissue, brain/untreated; Disease: brain cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser) CDKs Substrate Antibody Cat#: 2324, PTMScan(R) Phospho-CDK Substrate Motif (K/RS*PXK/R) Immunoaffinity Beads Cat#: 1981
Curated Info

20

Guo A (2011) CST Curation Set: 12738; Year: 2011; Biosample/Treatment: tissue, brain/untreated; Disease: brain cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXS*P, S*PXK/R) Immunoaffinity Beads Cat#: 1982
Curated Info

21

Guo A (2011) CST Curation Set: 12739; Year: 2011; Biosample/Treatment: tissue, brain/untreated; Disease: brain cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXS*P, S*PXK/R) Immunoaffinity Beads Cat#: 1982
Curated Info

22

Fang WQ, et al. (2011) Cdk5-mediated phosphorylation of Axin directs axon formation during cerebral cortex development. J Neurosci 31, 13613-24
21940452   Curated Info

23

Guo A (2011) CST Curation Set: 12476; Year: 2011; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

24

Yu Y, et al. (2011) Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling. Science 332, 1322-6
21659605   Curated Info

25

Wang Y, et al. (2011) Spatial phosphoprotein profiling reveals a compartmentalized extracellular signal-regulated kinase switch governing neurite growth and retraction. J Biol Chem 286, 18190-201
21454597   Curated Info

26

Huttlin EL, et al. (2010) A tissue-specific atlas of mouse protein phosphorylation and expression. Cell 143, 1174-89
21183079   Curated Info

27

Wiƛniewski JR, et al. (2010) Brain phosphoproteome obtained by a FASP-based method reveals plasma membrane protein topology. J Proteome Res 9, 3280-9
20415495   Curated Info

28

Shinkai-Ouchi F, et al. (2010) Identification and structural analysis of C-terminally truncated collapsin response mediator protein-2 in a murine model of prion diseases. Proteome Sci 8, 53
20961402   Curated Info

29

Tweedie-Cullen RY, Reck JM, Mansuy IM (2009) Comprehensive mapping of post-translational modifications on synaptic, nuclear, and histone proteins in the adult mouse brain. J Proteome Res 8, 4966-82
19737024   Curated Info

30

Zhou J (2009) CST Curation Set: 7441; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

31

Zhou J (2009) CST Curation Set: 7443; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

32

Zhou J (2009) CST Curation Set: 7440; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

33

Zhou J (2009) CST Curation Set: 7442; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

34

Zhou J (2009) CST Curation Set: 7431; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pSP
Curated Info

35

Zhou J (2009) CST Curation Set: 7428; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pSP
Curated Info

36

Zhou J (2009) CST Curation Set: 7429; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pSP
Curated Info

37

Zhou J (2009) CST Curation Set: 7413; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: HXXp[ST]
Curated Info

38

Zhou J (2009) CST Curation Set: 7414; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: HXXp[ST]
Curated Info

39

Zhou J (2009) CST Curation Set: 7412; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: HXXp[ST]
Curated Info

40

Zhou J (2009) CST Curation Set: 7411; Year: 2009; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: HXXp[ST]
Curated Info

41

Zhou J (2008) CST Curation Set: 4863; Year: 2008; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-Thr-Pro Motif Antibody (polyAB) Cat#: 3003, PTMScan(R) Phospho-Thr-Pro Motif (T*P) Immunoaffinity Beads Cat#: 1996
Curated Info

42

Zhou J (2008) CST Curation Set: 4864; Year: 2008; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-Thr-Pro Motif Antibody (polyAB) Cat#: 3003, PTMScan(R) Phospho-Thr-Pro Motif (T*P) Immunoaffinity Beads Cat#: 1996
Curated Info

43

Zhou J (2008) CST Curation Set: 4860; Year: 2008; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info

44

Zhou J (2008) CST Curation Set: 4779; Year: 2008; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pTXR Antibodies Used to Purify Peptides prior to LCMS: Phospho-Threonine-X-Arginine Antibody Cat#: 2351, PTMScan(R) Phospho-Thr-X-Arg Motif (T*XR) Immunoaffinity Beads Cat#: 1988
Curated Info

45

Collins MO, et al. (2008) Phosphoproteomic analysis of the mouse brain cytosol reveals a predominance of protein phosphorylation in regions of intrinsic sequence disorder. Mol Cell Proteomics 7, 1331-48
18388127   Curated Info

46

Zhou J (2008) CST Curation Set: 4323; Year: 2008; Biosample/Treatment: tissue, brain/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY
Curated Info

47

Cole AR, et al. (2007) Collapsin response mediator protein-2 hyperphosphorylation is an early event in Alzheimer's disease progression. J Neurochem 103, 1132-44
17683481   Curated Info

48

Guo A (2007) CST Curation Set: 2715; Year: 2007; Biosample/Treatment: tissue, brain/-; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXS*P, S*PXK/R) Immunoaffinity Beads Cat#: 1982
Curated Info

49

Guo A (2007) CST Curation Set: 2718; Year: 2007; Biosample/Treatment: tissue, brain/-; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST](D/E)X(D/E)
Curated Info

50

Guo A (2007) CST Curation Set: 2682; Year: 2007; Biosample/Treatment: tissue, brain/-; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) ATM/ATR Substrate Antibody Cat#: 2851
Curated Info

51

Cole AR, et al. (2006) Distinct priming kinases contribute to differential regulation of collapsin response mediator proteins by glycogen synthase kinase-3 in vivo. J Biol Chem 281, 16591-8
16611631   Curated Info

52

Trinidad JC, et al. (2006) Comprehensive identification of phosphorylation sites in postsynaptic density preparations. Mol Cell Proteomics 5, 914-22
16452087   Curated Info